OpenAlex
PricingAboutJobs
Log inGet started
Work

Phase lb study of LEE011 and BYL719 in combination with letrozole in estrogen receptor-positive, HER2-negative breast cancer (ER+, HER2− BC).

HTML

Year: 2014
Type: conference-abstract
Source: Journal of Clinical Oncology
DOI: 10.1200/jco.2014.32.15_suppl.533
Authors: Pamela N. Munster, Erika Paige Hamilton, Catherine Franklin, Suraj Bhansali, Kitty Wan, Becker Hewes, Dejan Juric
Institutions: UCSF Helen Diller Family Comprehensive Cancer Center, Sarah Cannon, Tennessee Oncology, Novartis (Switzerland), Harvard University, Massachusetts General Hospital
Language: English

Topic: Advanced Breast Cancer Therapies
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: ribociclib, alpelisib, letrozole, estrogen receptor-positive breast cancer, HER2-negative breast cancer, CDK4/6 inhibitors, PI3K inhibitors, aromatase inhibitor resistance, endocrine therapy resistance, combination therapy, dose-limiting toxicity, maximum tolerated dose, pharmacokinetics, postmenopausal women, metastatic breast cancer
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W1470988277
Cites:
Cited by: 36
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Subscribe
Supporters
Legal
Privacy
Accessibility
Terms
Security